Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma

C Dierks, J Seufert, K Aumann, J Ruf, C Klein, S Kiefer… - Thyroid, 2021 - liebertpub.com
Background: Anaplastic thyroid carcinoma (ATC) and metastatic poorly differentiated thyroid
carcinomas (PDTCs) are rare aggressive malignancies with poor overall survival (OS) …
被引用次数：168 相关文章
[HTML] nih.gov

[HTML][HTML] Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma

C Dierks, J Seufert, K Aumann, J Ruf, C Klein, S Kiefer… - Thyroid, 2021 - ncbi.nlm.nih.gov
Background: Anaplastic thyroid carcinoma (ATC) and metastatic poorly differentiated thyroid
carcinomas (PDTCs) are rare aggressive malignancies with poor overall survival (OS) …

[引用][C] Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma

C Dierks, J Seufert, K Aumann, J Ruf, C Klein, S Kiefer… - Thyroid, 2021 - cir.nii.ac.jp
Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic
and Poorly Differentiated Thyroid Carcinoma | CiNii Research CiNii 国立情報学研究所 学術 …

Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.

C Dierks, J Seufert, K Aumann, J Ruf… - … : Official Journal of the …, 2021 - europepmc.org
Background: Anaplastic thyroid carcinoma (ATC) and metastatic poorly differentiated thyroid
carcinomas (PDTCs) are rare aggressive malignancies with poor overall survival (OS) …

Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.

C Dierks, J Seufert, K Aumann, J Ruf, C Klein… - …, 2021 - search.ebscohost.com
Background: Anaplastic thyroid carcinoma (ATC) and metastatic poorly differentiated thyroid
carcinomas (PDTCs) are rare aggressive malignancies with poor overall survival (OS) …

Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma

C Dierks, J Seufert, K Aumann, J Ruf… - … : official journal of …, 2021 - pubmed.ncbi.nlm.nih.gov
Background: Anaplastic thyroid carcinoma (ATC) and metastatic poorly differentiated thyroid
carcinomas (PDTCs) are rare aggressive malignancies with poor overall survival (OS) …
[PDF] academia.edu

[PDF][PDF] Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma

C Dierks, J Seufert, K Aumann, J Ruf, C Klein, S Kiefer… - THYROID, 2021 - academia.edu
Background: Anaplastic thyroid carcinoma (ATC) and metastatic poorly differentiated thyroid
carcinomas (PDTCs) are rare aggressive malignancies with poor overall survival (OS) …
[PDF] arztwelt.de

[PDF][PDF] Combination of Lenvatinib and Pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma

C DIERKS, J SEUFERT, K AUMANN, J RUF, C KLEIN… - Thyroid, 2021 - arztwelt.de
Im Vergleich mit den differenzierten Schilddrüsenkarzinomen sind diese Tumorentitäten
durch eine hohe Mutationslast charakterisiert. Weitere Merkmale sind erhöhte PD-L1 …

Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma

C Dierks, J Seufert, K Aumann, J Ruf, C Klein… - …, 2021 - research.uni-luebeck.de
Background: Anaplastic thyroid carcinoma (ATC) and metastatic poorly differentiated thyroid
carcinomas (PDTCs) are rare aggressive malignancies with poor overall survival (OS) …

[引用][C] Combination of Lenvatinib and Pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma

C Dierks, J Seufert, K Aumann, J Ruf, C Klein… - …, 2021 - freidok.uni-freiburg.de